Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Combination antiviral therapy for hepatitis C Examples Brand Name Chemical Name Rebetron interferon alfa-2b and ribavirin Peg-Rebetron peginterferon alfa-2b and ribavirin Pegasys and Copegus peginterferon alfa-2a and ribavirin How It Works Treatment helps prevent the virus that causes hepatitis C from reproducing in the body.
Cover 0519.qxd This weeks UK Patents and Design Journal (PDJ) contained details of one SPC grant and notification of three SPCs entering into force.ribavirin on EP643970 entered into force April 16 th and expires in April 2010.
author: GWhite
Cover 0519.qxd page 1
author: GWhite
Big pharma set to move into HIV/hepatitis co-infection niche - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Chronic hepatitis B and- C: a chronic lack of effective treatment - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
APRICOT trial reveals promising therapeutic potential for the HIV/HCV co-morbid population - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
BioPortfolio Client Press Releases Site Map FDA to Initiate Study of HEMOLINK in Orthopedic Surgery Mediatum - Management Boutique at the Interface between Pharmaceutical and Biotech Industry Biotech Tracker News - Study Supports BioBypass Development Biotech Tracker News - Onyx’s Raf Inhibitor Shows Promise Biotech Tracker News - Boston Scientific Presents Additional Coated Stent Data Biotech Tracker News - Treatment...
HepCgen genotyping service helps fight Hepatitis C, a ‘silent epidemic’ - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Biotech Tracker News - FDA Committee Will Review Pegasys - Copegus Combination Submitted this past June, the marketing application has been given fast track status.- Copegus differs from a ribavirin formulation marketed by Schering-Plough (NYSE: SGP ) as both the single agent Rebetol and the co-packaged Rebetron (Rebetol plus interferon alfa-2b).
Biotech Tracker News - FDA Committee Recommends Pegasys- Copegus Combo - - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - FDA Committee Recommends Pegasys Copegus Combo- November 15, 2002 Roche’s (Swiss: ROG) Pegasys / Copegus (peginterferon alfa-2b / ribavirin) co-packaged hepatitis C therapy received unanimous recommendation from the FDA’s Antiviral Drugs Advisory Committee.
BioPortfolio Limited Both GSK and Gilead are obvious candidates and in light of similar challenges between HBV/HCV and HIV, Datamonitor expects increased portfolio synergies for the management of chronic viral conditions; 10 Summary 11 Key metrics 12 CHAPTER 2 MARKET SEGMENTATION & DEFINITION 29 Strategic scope and focus 29 Market definition 30 Hepatitis B 30 Disease definition 30 Epidemiology 34...
No Title The specific mechanism by which merimepodib enhances ribavirin activity is not known, but it has been suggested that merimepodib may increase the likelihood of ribavirin incorporation into viral RNA during replication, resulting either in decreased viral replication or in the production of immature or defective viral particles.
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 60
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 12
author: Windows 9x/NT/2000/XP User
subject: None
Vertex Pharmaceuticals Press Release May 25, 2004 Vertex Pharmaceuticals Announces Plans for the METRO Study: Triple Combination of Merimepodib, Pegasys® and Copegus® in Hepatitis C Patients - Roche Agrees to Provide Pegasys and Copegus for Phase IIb Clinical Trial - Cambridge, MA, May 25, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the design of a Phase IIb clinical study that it plans to...
http://www.aurorabio.com/pdfs/Vertex_Q304.pdf com Next 24 wks Pegasys + Copegus (responders only) First 24 wks.Copegus ® + MMPD/ placebo 24 wk.
http://www.aurorabio.com/pdfs/Q204_072604.pdf follow- up Patients w/ undetectable viral load receive Pegasys + Copegus only 24 weeks Patients receive Pegasys ® + Copegus ® + MMPD OR placebo www.
Microsoft Word - Working File.doc page 9
author: msulliva
http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_00.pdf page 18
author: ryo1
duplicates:http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_07.pdf
http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_00.pdf page 17
author: ryo1
duplicates:http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_07.pdf
http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_00.pdf page 15
author: ryo1
duplicates:http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_06.pdf
http://www.chugai-pharm.co.jp/pdf/annual_report/2003/AR03e_00.pdf Start of the New Chugai —As a most important member of the Roche Group, Chugai aims to become a top Japanese pharmaceutical company Annual Report 2003 March Forward- Looking Statements This annual report includes forward- looking statements pertaining to the business and prospects of the Company
author: ryo1
Therapeutic Biological Approvals 97 South Street Hopkinton, MA 01748 License 1258 02/05/1999 PEGASYS Peginterferon alfa-2a Treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been previously treated with interferon alfa 103964 / 0 Hoffman-La Roche, Inc 340 Kingsland Street Nutley, NJ 07110-1199 License 0136 10/16/2002 PEGASYS Peginterferon alfa-2a Expanded Indication for...
Office of Drug Safety: Patient Labeling and Risk Communitation Food and Drug Administration • Center for Drug Evaluation and Research Office of Drug Safety Search Patient Labeling and Risk Communication FDA-Approved Patient Labeling Patient Package Inserts.- For some prescription medicines, FDA approves special patient materials to instruct patients about the safe use of the product
author: PhillipsJ
untitled (Development Pipeline) 1 Chugai Pharmaceutical Co., Ltd (Appendix 2) Development pipeline (as of February 13 th 2004) Development code Indication # Additional indication Stage (Filing date) INN Trade mark Dosage form Origin (Collaborator) Mechanism of Action Oncology CGS20267 Breast cancer in postmenopausal women Filed Jul
